Cardio Diagnostics Holdings Inc. (CDIO) - Ekuitas Perusahaan

Cardio Diagnostics generates revenue through the implementation of epigenetic research, where the Epi+Gen CHD test plays a pivotal role in the personalized prevention of cardiac pathologies. The market trend, visualized in monetary terms and currently sitting at 0.01, confirms growth potential, as existing datasets allow for a manifold increase in screening volume without significant expenditures. Its status as a cardiology innovator and the medical community's trust in the accuracy of AI-driven analytics establish the brand as an industry leader.

To assess the long-term sustainability of Cardio Diagnostics (CDIO), an investor must analyze the difference between total assets and liabilities, which allows for the verification of the business's real value between reporting periods. An analysis of the balance sheet capitalization structure confirms capital preservation, providing the financial foundation for scaling sales of Epi+Gen CHD epigenetic tests and developing personalized cardiological prevention.